Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022

被引:9
作者
Torres-Canchala, Laura [1 ,2 ]
Cleves-Luna, Daniela [2 ]
Arias-Valderrama, Oriana [1 ,2 ]
Candelo, Estephania [1 ]
Guerra, Maria Angelica [1 ]
Pachajoa, Harry [2 ,3 ]
Olaya, Manuela [1 ,2 ]
机构
[1] Fdn Valle Lili, Ctr Invest Clin, Cali 760032, Colombia
[2] Univ Icesi, Fac Ciencias Salud, Dept Med, Cali 760031, Colombia
[3] Univ Icesi, Ctr Invest Enfermedades Raras & Malformac Congenit, Cali 760031, Colombia
来源
CHILDREN-BASEL | 2023年 / 10卷 / 01期
关键词
adjuvant therapy child; adult; adult-onset recurrent respiratory papillomatosis juvenile-onset papillomatosis; recurrent respiratory papillomatosis; systemic bevacizumab; treatment; EXPERIENCE;
D O I
10.3390/children10010054
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy. Objective: This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB treatment. Methods: Participants with RRP of all genders are included in this scoping review. There were no exclusion criteria (country, language, or document type). The information sources included experimental, quasi-experimental, and analytical observational studies. Unpublished data will not be covered, but gray literature was covered. Screening, paper selection, and data extraction were all done by two independent reviewers. This procedure was performed blindly. Results: Of the 175 unique records found, 15 were eligible for inclusion. Fourteen studies were included after applying inclusion and exclusion criteria. Thirty-four patients in these studies came from the United States, India, Germany, Colombia, Argentina, Chile, and Spain. In total, 17 and 34 patients were below 18 years old and were adults respectively. The most commonly reported dose was 10 mg/kg, which was received by 25 (73.5%) patients. According to reports, 58.8% of patients completed the questionnaire. Twelve (35%) patients did not require a repeat surgery. The time interval between surgical procedures has increased for patients who require them. Conclusion: SB may be a promissory treatment and control option for RRP. More research is needed to evaluate the efficiency and adverse effects in various populations.
引用
收藏
页数:13
相关论文
共 30 条
[11]   Recurrent Respiratory Papillomatosis and Bevacizumab Treatment [J].
Fernandez-Bussy, Sebastian ;
Labarca, Gonzalo ;
Vial, Macarena R. ;
Soto, Rodrigo ;
Mehta, Hiren J. ;
Jantz, Michael ;
Majid, Adnan ;
Burotto, Mauricio .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (04) :539-541
[12]   Recurrent respiratory papillomatosis: A state-of-the-art review [J].
Fortes, Helena Ribeiro ;
von Ranke, Felipe Mussi ;
Escuissato, Dante Luiz ;
Araujo Neto, Cesar Augusto ;
Zanetti, Glaucia ;
Hochhegger, Bruno ;
Souza, Carolina Althoff ;
Marchiori, Edson .
RESPIRATORY MEDICINE, 2017, 126 :116-121
[13]   Bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in an infant [J].
Gates, Christopher ;
Tomboc, Patrick ;
Allison, Andrew ;
Carr, Michele .
INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2020, 129
[14]   Recurrent Respiratory Papillomatosis With Complete Response to Systemic Bevacizumab Therapy [J].
Gorelik, Daniel ;
Frantz, Amy ;
Dome, Jeffrey S. ;
Reilly, Brian K. .
ENT-EAR NOSE & THROAT JOURNAL, 2024, 103 (02) :100-101
[15]   Systemic and Intralesional Bevacizumab in Juvenile Onset Recurrent Respiratory Papillomatosis: A Report of Two Cases [J].
Goyal, Arun ;
Kapoor, Dhruv ;
Saha, Richa .
INDIAN JOURNAL OF OTOLARYNGOLOGY AND HEAD & NECK SURGERY, 2022, 74 (SUPPL 3) :5098-5101
[16]   Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: A case report [J].
Hamdi, Osama ;
Dome, Jeff ;
Zalzal, George ;
Preciado, Diego .
INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2020, 128
[17]   TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS WITH HUMAN-LEUKOCYTE INTERFERON - RESULTS OF A MULTICENTER RANDOMIZED CLINICAL-TRIAL [J].
HEALY, GB ;
GELBER, RD ;
TROWBRIDGE, AL ;
GRUNDFAST, KM ;
RUBEN, RJ ;
PRICE, KN .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (07) :401-407
[18]   Current and Future Management of recurrent Respiratory Papillomatosis [J].
Ivancic, Ryan ;
Iqbal, Hassan ;
deSilva, Brad ;
Pan, Quintin ;
Matrka, Laura .
LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY, 2018, 3 (01) :22-34
[19]   SITES OF PREDILECTION IN RECURRENT RESPIRATORY PAPILLOMATOSIS [J].
KASHIMA, H ;
LEVENTHAL, B ;
MOUNTS, P ;
HRUBAN, RH .
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 1993, 102 (08) :580-583
[20]   Airway Papillomatosis: New Treatments for an Old Challenge [J].
Kumar, Nankee ;
Preciado, Diego .
FRONTIERS IN PEDIATRICS, 2019, 7